Valerio Therapeutics SA 2012 IR
The report outlines BioAlliance Pharma's strategic and financial progress during the 2012 fiscal year, highlighting the launch of the Livatag Phase III clinical trial for primary liver cancer and the continuation of the Validive Phase II trial. It details the registration of Sitavig in eight European countries and the submission of its registration dossier in the United States. Additionally, the company expanded its commercial partnerships, including a licensing agreement with Vestiq Pharmaceuticals for Oravig in the U.S. and a distribution contract in Iran for Loramyc. The report also includes the company's Social and Environmental Responsibility disclosures, focusing on employment, health and safety, and waste management.
Company: Valerio Therapeutics SA
Sector: Professional & technical services
Country: France
Year: 2012
Type: IR
Pages: 231
Back to company
Valerio Therapeutics SA
Reference Document
The report outlines BioAlliance Pharma's strategic and financial progress during the 2012 fiscal year, highlighting the launch of the Livatag Phase III clinical trial for primary liver cancer and the continuation of the Validive Phase II trial. It details the registration of Sitavig in eight European countries and the submission of its registration dossier in the United States. Additionally, the company expanded its commercial partnerships, including a licensing agreement with Vestiq Pharmaceuticals for Oravig in the U.S. and a distribution contract in Iran for Loramyc. The report also includes the company's Social and Environmental Responsibility disclosures, focusing on employment, health and safety, and waste management.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Jan 1, 2012 - Dec 31, 2012
Fiscal Year
2012
Published
Apr 18, 2013
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees